Drug Database
HE

hepatitis-B vaccine + 1018-ISS (V270 / V270 / Heplisav)

✓ Approved

Merck & Co. · TLR9 · 重组蛋白

什么是 hepatitis-B vaccine + 1018-ISS?

hepatitis-B vaccine + 1018-ISS 是一种重组蛋白,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名V270, V270, Heplisav
公司Merck & Co.
药物类别重组蛋白, 疫苗
分子靶点TLR9,
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

hepatitis-B vaccine + 1018-ISS 作用于 2 个分子靶点:

TLR9toll like receptor 9 (CD289)
(S)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

hepatitis-B vaccine + 1018-ISS 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsHepatitis B✓ Approved

相关研究文献

PubMedHepatology forum2026-11-17

Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review.

Zhu Kai K, Wu Eric E, Tam Benson B, Yoshida Eric M EM et al.

We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.

PMID 43042239
阅读全文 →
PubMedBMC gastroenterology2026-11-17

Incidence of liver cancer and decompensated cirrhosis amongst hepatitis B and C notifications in Tasmania- a data linkage study.

Ibegu Maria M, Le Tuan Nguyen Anh A, Stephens Nicola N, de Graaff Barbara B

Liver cancer is a leading cause of cancer-related death globally, with both incidence and mortality rates rising sharply in Australia over the past three decades. Chronic hepatitis B and C are major contributors to liver cancer, and its common precursor, decompensated cirrhosis. This study assessed the incidence of liver cancer and decompensated cirrhosis among individuals with hepatitis B and C in Tasmania. A retrospective population-based study was conducted using linked datasets. The cohort included all individuals with a notification for hepatitis B and/or C in Tasmania from 1995 to 2022. Cases were linked to the Tasmanian Cancer Register and admitted patient data from Tasmanian public hospitals. Incidence rates per 1,000 person-years were calculated for liver cancer and decompensated cirrhosis. Between 1995 and 2022, 1,280 hepatitis B (55.5% male) and 6,658 hepatitis C (64.3% male) notifications were recorded in Tasmania. A total of 145 liver cancer registrations and 270 decompensated cirrhosis-related admissions were observed. Among individuals with hepatitis B, the incidence rates were 5.39 per 1,000 person-years for liver cancer and 3.00 per 1,000 person-years for decompensated cirrhosis. Among those with hepatitis C, corresponding rates were 2.33 and 5.02 per 1,000 person-years. While the number of liver-related outcomes was relatively low and did not support more detailed analyses, a trend towards higher incidence rates was observed over the study period. These findings highlight the burden of liver-related complications among individuals with hepatitis B and C in Tasmania. Liver cancer was more common among those with hepatitis B, while decompensated cirrhosis was more frequent among those with hepatitis C. Observed trends should be interpreted cautiously, as they may reflect changes in population characteristics, surveillance, and healthcare engagement. Strengthening testing, treatment uptake, and long-term monitoring is essential to reduce the burden of advanced liver disease in this regional setting.

PMID 43040487
阅读全文 →
PubMedPakistan journal of medical sciences2026-11-17

ELISA screening results for HAV, HBV, HCV, HIV: A retrospective study.

Goktas Olgun O, Deniz Ismail Emre IE, Ercan Ilker I

To retrospectively evaluate the hepatitis A, B, C, and human immunodeficiency virus screening results using the ELISA method in primary care. This study was conducted retrospectively using the available recorded data of individuals registered with the Bursa Uludag University Family Health Center who underwent ELISA measurement between January 2020 to December 2024. The study included data from a total of 2,918 individuals over the age of 18 who met the inclusion criteria. In statistical comparisons, α was taken as 0.05. Data analysis was performed using the IBM SPSS Statistics 28 statistical package program. Of the 2918 individuals who participated in the study, 1528 (52.4%) were female, and 1390 (47.6%) were male. The median age of the participants was 24 (18-83). Of the participants, 1355 (46.4%) were healthcare workers, while 1563 (53.6%) were not. Hospital referrals were made in 37 (1.3%) individuals, while 2881 (98.7%) were not referred. Anti-HAVIgM and HBsAg positivity was significantly higher in the non-healthcare worker group compared to the healthcare worker group (p=0.013, p=0.038). Anti-HBcIgG, anti-HBs positivity, and Hepatitis-B vaccination were higher in the healthcare worker group (p<0.001). There was a statistically significant difference between HBsAg and anti-HBs (p<0.001). Hospital referral rates were higher in those positive for Hepatitis A, B, C, and HIV antibodies, while they were significantly lower in those with anti-HBs positivity and those vaccinated against Hepatitis-B (p<0.001). ELISA screenings, Hepatitis-B antibody levels and vaccination status were higher in healthcare workers, while Hepatitis-B antigen levels were higher in non-healthcare workers. Hospital referral rates were also higher in those with high Hepatitis A, B, C, and HIV antibody levels. Our ELISA screening results for infections in family medicine are important for diagnosis, treatment, follow-up, and referral to other clinics.

PMID 43042247
阅读全文 →
PubMedHepatology forum2026-11-17

Hepatitis B surface antigen seroclearance after nucleos(t)ide analogue discontinuation in non-cirrhotic patients with chronic hepatitis B.

Melekoglu Ellik Zeynep Z, Sah Unal Fatma Tugce FT, Koc Ozge O, Tunc Esra E et al.

This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment. Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-continued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (<50 years) at treatment discontinuation (p=0.023) and elevated baseline serum AST levels (p=0.018) as independent predictors of HBsAg seroclearance. Seventy-five percent of these patients experienced HBsAg seroconversion to hepatitis B surface antibody (anti-HBs). After NA discontinuation, 67% of the patients (49/73) in the treatment-discontinuation group experienced virological relapse. Of these, 29 developed clinical relapse and reinitiated antiviral treatment, while the remaining 20 patients continued follow-up without antiviral therapy. Most clinical relapses (72%) occurred within the first 3 months after treatment discontinuation. Virological relapse did not occur in the other 24 patients. Overall, 44 patients in the treatment-discontinuation group (60%) did not require retreatment during follow-up. Discontinuation of long-term NA treatment in selected HBeAg-negative patients was associated with HBsAg seroclearance and may contribute to a functional cure. Close post-discontinuation surveillance remains essential for early detection and management of clinical relapse.

PMID 43042248
阅读全文 →
PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-17

Alginate-DNA Core-Shell Hydrogel Microspheres Program Antigen Release Kinetics for Potent Single-Dose Subunit Vaccination.

Shen Fengyun F, Yan Lingling L, Sun He H, Wu Junjie J et al.

Conventional vaccine sustained release strategies exhibit monophasic antigen kinetics that fail to align with the temporal order of T and B cell activation, limiting single-dose efficacy. Using a protein-carrier peptide vaccine model, we designed an alginate-DNA core-shell hydrogel microsphere that programmed differential antigen release kinetics through orthogonal loading mechanisms. Physical encapsulation enabled carrier protein release within 3 days to prime T cells, while DNA cross-linking sustained epitope-carrier protein conjugate release over 11 days to drive B cell responses, achieving a release interval exceeding 8 days that orchestrates sequential T and B cell activation. In a single immunization, this strategy induces significantly higher epitope-specific IgG titers compared to formulations with either co-rapid or co-sustained release. A SARS-CoV-2 peptide vaccine based on our strategy elicits substantially stronger humoral immunity than traditional aluminum-adjuvanted vaccines. This work establishes orthogonal loading-mediated kinetic programming as a versatile platform for next-generation single-injection subunit vaccines.

PMID 43042745
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hepatitis-B vaccine + 1018-ISS